A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide - PubMed
5 hours ago
- #PCSK9 inhibitor
- #LDL cholesterol
- #cardiovascular disease
- Enlicitide decanoate, an oral PCSK9 inhibitor, was tested in a placebo-controlled trial for lowering LDL cholesterol.
- The trial included adults with a history of atherosclerotic cardiovascular disease or at risk for it, with specific LDL cholesterol level criteria.
- Participants were randomized to receive either 20 mg of enlicitide or placebo daily for 52 weeks.
- The primary endpoint was the mean percent change in LDL cholesterol from baseline to week 24.
- Results showed a significant reduction in LDL cholesterol levels with enlicitide compared to placebo at both 24 and 52 weeks.
- Secondary endpoints, including changes in non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) levels, also favored enlicitide.
- The incidence of adverse events was similar between the enlicitide and placebo groups.
- The study concluded that enlicitide effectively lowers LDL cholesterol in at-risk populations.